

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE SECOND QUARTER OF 2024

This announcement is made by Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the second quarter of 2024, the Company achieved a total product revenue exceeding RMB2.0 billion, representing a robust year-over-year growth of approximately 50%. Our comprehensive portfolio offering and solid franchise, as well as broad National Reimbursement Drug List coverage and market access, give us a significant competitive advantage in meeting diverse patient needs for innovative medicines. The sales momentum of TYVYT[®] (sintilimab injection) and other key products remained strong, while new products increasingly contributed to revenue, underscoring our effective commercial and marketing strategies.

The Company aims to build both oncology and general biomedicine (including cardiovascular and metabolism, autoimmune and ophthalmology) fields as key growth pillars for the Company's long-term development. Currently, the Company has ten approved products, four assets under the review by the National Products Administration of China, four assets in Phase III or pivotal clinical studies, and 18 additional molecules in clinical studies. The Company believes that its robust innovative pipeline with broad market potential will provide a solid foundation for its long-term sustainable growth.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
August 8, 2024

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as Independent Non-executive Directors.